LLY Stock: Insider Activity, Filings & Research
Drillr aggregates AI research, SEC filings, earnings signals and alt-data for LLY. 10 published articles.
Insider Activity
Over the trailing 90-day window, LLY insiders executed two open-market sales totaling $15.8M with zero purchases, resulting in a 0/100 insider sentiment score. The notable activity consisted of two sales by Lilly Endowment Inc, a former 10% shareholder, totaling $15.8M on a single date. Despite the net insider selling, the stock returned 5.7% over the period, while institutional investors showed accumulation via 13F filings. The absence of offsetting purchases and the concentration of selling activity from a single shareholder entity reflect bearish positioning from this constituency, though broader institutional behavior remains constructive.
Updated Jun 4, 2026 · based on SEC Form 4 filings · not investment advice
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 19, 2026 | LUCIANO JUAN Rdirector | Grant | 16 | $988.09 |
| May 19, 2026 | Alvarez Ralphdirector | Grant | 13 | $988.09 |
| May 19, 2026 | Sulzberger Gabrielledirector | Grant | 5 | $988.09 |
| May 19, 2026 | Fyrwald J Erikdirector | Grant | 10 | $988.09 |
| May 7, 2026 | LILLY ENDOWMENT INCother: Former 10% Shareholder | Sell | 13,620 | $995.23 |
| May 7, 2026 | LILLY ENDOWMENT INCother: Former 10% Shareholder | Sell | 2,208 | $996.18 |
| Apr 21, 2026 | LUCIANO JUAN Rdirector | Grant | 17 | $919.90 |
| Apr 21, 2026 | Alvarez Ralphdirector | Grant | 13 | $919.90 |
| Apr 21, 2026 | Sulzberger Gabrielledirector | Grant | 5 | $919.90 |
| Apr 21, 2026 | Fyrwald J Erikdirector | Grant | 11 | $919.90 |
| Mar 17, 2026 | LUCIANO JUAN Rdirector | Grant | 16 | $989.12 |
| Mar 17, 2026 | Fyrwald J Erikdirector | Grant | 10 | $989.12 |
| Mar 17, 2026 | Sulzberger Gabrielledirector | Grant | 5 | $989.12 |
| Mar 17, 2026 | Alvarez Ralphdirector | Grant | 13 | $989.12 |
| Feb 18, 2026 | LUCIANO JUAN Rdirector | Grant | 15 | $1036.05 |
Source: LLY SEC Form 4 filings, latest May 19, 2026. For informational purposes only — not investment advice.
Research
LLY: $2.3B Ajax Buy Hedges Mounjaro Patent Cliff
Eli Lilly's $2.3 billion Ajax Therapeutics acquisition reveals a critical divergence in large-cap pharma M&A strategy that the market has mispriced. While Merck and Pfizer scramble to replace patent cliff revenue with expensive blockbuster acquisitions, Lilly is buying rare-disease optionality from a position of GLP-1 strength. Long LLY versus short MRK/PFE targets 8-12% relative return over six months as earnings reveal the cost of desperate dealmaking.
MRKPFEBMYEli Lilly's Kelonia Acquisition: Does It Unlock Genetic Medicine Upside Beyond GLP-1?
Eli Lilly closes Kelonia Therapeutics acquisition, integrating gene therapies for cancer that extend growth beyond GLP-1 drugs. Shares look undervalued at 55x PE versus gene therapy peers. Long LLY to $1,050 in 12 months, breaks without Phase 1 progress by mid-2027.
Pharma Tariffs: Buy LLY & AMGN, Sell PFE & MRK — Here's Why
Trump policies eroding Europe's pharma lead via tariffs favor US manufacturing-heavy Eli Lilly and Amgen, with strong growth and margins, while Pfizer and Merck's global chains invite cost squeezes. J&J and AbbVie sit in the middle with diversification. Rank: Buy LLY/AMGN, sell PFE/MRK.
AMGNABBVJNJTrump 100% Pharma Tariffs: PFE and MRK Face $200M Hit While LLY Gains 25%
Trump's proposed 100% pharma tariffs and China's biotech surge, per April 11 CNBC, threaten Europe's manufacturing edge, hiking costs for PFE (-2.8% 1M) and MRK (-5.1% 1M) while LLY's US focus drives 25% 2026 growth. Supply chain filings flag $100-200M hits; investors should fade exposed names, buy domestic leaders. Next catalysts: Earnings tariff disclosures and China trade flows.
PFEMRKTMOLLY Acquires CNTA for $7.8B: Options Traders Pile In as Stock Surges 44%
Options traders swarmed CNTA calls after Eli Lilly confirmed its $7.8B buyout, driving a 44% surge to $39.61 amid closing buzz. The deal slots orexin sleep assets into LLY's obesity powerhouse, backed by $65B 2025 revenue and $80B+ 2026 guide. Bullish: Synergies outweigh premium in a 25x fwd P/E beast.
CNTAPharma Tariffs: LLY and AMGN Win While PFE and MRK Face Margin Squeeze
Trump's pharma import tariffs shield U.S.-focused drugmakers like Eli Lilly and Amgen from cost hikes while pressuring import-reliant Pfizer and Merck. Analysis ranks six majors by exposure, highlighting financials and guidance. Domestic winners eye margin expansion amid onshoring push.
AMGNABBVJNJLLY Stock Dips on Foundayo Approval — Is the GLP-1 Oral Drug a NVO Killer?
Eli Lilly's shares fell despite Foundayo (orforglipron) FDA approval due to geopolitical tensions, but the oral GLP-1's no-restrictions profile positions it to challenge Novo's injectable dominance. LLY's stellar growth (45% revenue surge) contrasts Novo's slowdown (-5-13% 2026 guidance), making the dip a potential entry point. Watch initial uptake and competitive filings for share shifts.
NVOLLY FDA Approval: Oral Obesity Pill Foundayo Threatens NVO's Wegovy as Revenue Surges 45%
FDA approval of Lilly's oral obesity pill Foundayo (orforglipron) intensifies rivalry with Novo's Wegovy, with Lilly's superior growth and oral convenience poised to capture needle-averse patients. NVO's guidance cuts highlight vulnerabilities, favoring LLY overweight amid 45% revenue surge vs. NVO's 6%. Key: Q1 2026 uptake and Medicare dynamics.
NVOFTC Insulin Crackdown: CVS Settles — What It Means for LLY, NVO, and WBA
CVS Health's recent settlement with the FTC over insulin pricing marks a pivotal moment in the pharmaceutical landscape. This article analyzes the potential winners and losers among pharmacies and drugmakers as regulatory scrutiny intensifies, highlighting key players like Eli Lilly, Novo Nordisk, and Walgreens Boots Alliance.
CVSWBANVOPharma Tariffs: LLY, TMO, CVS Supply Chain Exposure Ranked by Risk
Trump's April 2 pharma tariff announcement highlights supply chain risks for LLY, TMO, and CVS, with SEC filings exposing China reliance. Stocks dipped mildly, but domestic manufacturing offers protection amid margin pressures.
PFEMRKTMO
Track LLY with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free